These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19248879)

  • 21. [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
    Varela M; Reig M; de la Mata M; Matilla A; Bustamante J; Pascual S; Turnes J; Aracil C; Del Val A; Pascasio JM; Rodríguez M; Bruix J
    Med Clin (Barc); 2010 May; 134(13):569-76. PubMed ID: 20036398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
    Waidmann O; Hofmann WP; Zeuzem S; Trojan J
    J Hepatol; 2011 Feb; 54(2):396-8. PubMed ID: 21111506
    [No Abstract]   [Full Text] [Related]  

  • 23. Baying for a flexible drug price.
    Lancet; 2009 Nov; 374(9704):1794. PubMed ID: 19944844
    [No Abstract]   [Full Text] [Related]  

  • 24. Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models.
    Navasa M; Bruix J
    Hepatology; 2010 Jan; 51(1):12-5. PubMed ID: 20034046
    [No Abstract]   [Full Text] [Related]  

  • 25. [Expert consensus on standardization of the management of primary liver cancer].
    Ye SL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):403-10. PubMed ID: 19645134
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatocellular carcinoma--what's new?
    Vullierme MP; Paradis V; Chirica M; Castaing D; Belghiti J; Soubrane O; Barbare JC; Farges O
    J Visc Surg; 2010 Feb; 147(1):e1-12. PubMed ID: 20595072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.
    Maluccio M; Covey A
    CA Cancer J Clin; 2012; 62(6):394-9. PubMed ID: 23070690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
    Spârchez Z
    Med Ultrason; 2012 Jun; 14(2):85-6. PubMed ID: 22675706
    [No Abstract]   [Full Text] [Related]  

  • 29. Liver tumors and loco-regional therapy.
    Vogel W
    Wien Med Wochenschr; 2013 Mar; 163(5-6):107-8. PubMed ID: 23456251
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients].
    Gómez Rodríguez R; Romero Gutiérrez M; González de Frutos C; de Artaza Varasa T; de la Cruz Perez G; Ciampi Dopazo JJ; Lanciego Pérez C; Gómez Moreno AZ
    Gastroenterol Hepatol; 2011 Oct; 34(8):524-31. PubMed ID: 21940068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.
    Hussain K; El-Serag HB
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):123-38. PubMed ID: 19305372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Right sided heart mass reveals hepatocellular carcinoma.
    Barbero C; Salizzoni S; Centofanti P; Molino F; Campisi P; Giorgi M; Rinaldi M
    Heart Lung Circ; 2012 Dec; 21(12):817-8. PubMed ID: 22841160
    [No Abstract]   [Full Text] [Related]  

  • 33. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R; Byrne MT; Tan A; Aucejo F
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma.
    Felga G; Salvalaggio PR; de Rezende MB; de Almeida MD
    J Hepatol; 2014 Jan; 60(1):229-30. PubMed ID: 24021423
    [No Abstract]   [Full Text] [Related]  

  • 35. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.
    Marrero JA; Kulik LM; Sirlin CB; Zhu AX; Finn RS; Abecassis MM; Roberts LR; Heimbach JK
    Hepatology; 2018 Aug; 68(2):723-750. PubMed ID: 29624699
    [No Abstract]   [Full Text] [Related]  

  • 36. Current approach to hepatocellular carcinoma.
    Abrams P; Marsh JW
    Surg Clin North Am; 2010 Aug; 90(4):803-16. PubMed ID: 20637949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reply to: "Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma".
    Sposito C; Mazzaferro V
    J Hepatol; 2014 Jan; 60(1):230-1. PubMed ID: 24018319
    [No Abstract]   [Full Text] [Related]  

  • 38. Developing better treatments in hepatocellular carcinoma.
    Duffy A; Greten T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Changed diagnosis and treatment of hepatocellular carcinoma].
    van Nieuwkerk CM; Rauws EA; Tytgat GN; Reeders JW; Jones AE; Gouma DJ
    Ned Tijdschr Geneeskd; 1996 Apr; 140(17):922-6. PubMed ID: 8676971
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatocellular carcinoma (primary cancer of the liver).
    Barbare JC; Boige V; Boudjema K; Lescesne R; Trinchet JC
    Gastroenterol Clin Biol; 2006 Sep; 30 Spec No 2():2S57-2S61. PubMed ID: 17151564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.